<DOC>
	<DOCNO>NCT01088529</DOCNO>
	<brief_summary>The goal clinical research study find treatment abiraterone acetate combination prednisone Luteinizing Hormone-Releasing Hormone ( LHRH ) analogue change tumor comparison treatment LHRH analogue alone . Objectives : Primary Objective : To assess difference pathologic stage &lt; pT2 Group A Group B . Secondary Objective : - To assess compare change level androgen ( pre , , post treatment ) serum , primary tumor microenvironment bone marrow Group A Group B . - To assess change biomarkers related androgen signal cancer-related pathway Group A Group B . - To assess difference rate positive surgical margin Group A Group B . - To assess safety profile abiraterone acetate low dose prednisone preoperative setting .</brief_summary>
	<brief_title>Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone ( LHRH ) Versus LHRH Prostate Cancer</brief_title>
	<detailed_description>Study Groups : Participants eligible take part study randomly assign ( flip coin ) 1 2 group : - Those Group A take abiraterone acetate , LHRH analogue , prednisone . - Those Group B receive LHRH analogue alone . Participants 2 3 chance place Group A 1 3 chance place Group B . Participants group receive study drug ( ) 3 month follow prostatectomy ( prostate surgery ) 2 4 week stop take study drug ( ) . Length Study : Participants receive study drug study 3 month surgery remove prostate 2-4 week later . Participants remove study disease get bad , experience intolerable side effect , study doctor feel best interest stop study . Long-Term Follow-Up : Participants return clinic 1 month , 3 month , 6 month , every 6 month ( 8 year ) surgery follow-up visit . Up 66 patient take part study . All enrol M. D. Anderson surgery .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>1 . Histological proof prostatic adenocarcinoma via minimum 6 core biopsy sample 2 . Clinical stage T1c T2 highgrade disease ( Gleason 's 810 ) initial biopsy , clinical stage T2bT2c Gleason 's grade &gt; /= 7 PSA &gt; 10ng/ml . 3 . No evidence metastatic disease determine CT scan bone scan . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; /= 1 5 . Patients adequate bone marrow function define absolute peripheral granulocyte count ( ANC ) &gt; 1,500 platelet count &gt; 100,000 . 6 . Normal pituitary adrenal function 7 . Patients deem candidate radical prostatectomy . 1 . Histological variant primary tumor ( histological variant adenocarcinoma ) ; neuroendocrine tumor 2 . Serious uncontrolled coexistent nonmalignant disease , include active uncontrolled infection 3 . Uncontrolled hypertension 4 . Abnormal Liver function 5 . Active symptomatic viral hepatitis chronic liver disease 6 . Clinically significant heart disease 7 . Other active malignancy 8 . History gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study drug 9 . Previous treatment abiraterone acetate 10 . Patients appropriate surgical candidate radical prostatectomy 11 . Prior chemotherapy radiation therapy prostate cancer . 12 . Condition situation , investigator 's opinion , may put patient significant risk , may confound study result , may interfere significantly patient 's participation study Note : There additional inclusion exclusion criterion . The study center determine meet criterion .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Neoadjuvant Prostate Cancer</keyword>
	<keyword>Abiraterone Acetate</keyword>
	<keyword>LHRHa</keyword>
	<keyword>high risk prostate cancer</keyword>
	<keyword>Radical prostatectomy</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Luteinizing Hormone-Releasing Hormone</keyword>
	<keyword>LHRH analogue</keyword>
</DOC>